Clinical trial
Study of the Effects of Fabrazyme Treatment on Lactation and Infants
NCT00230607 · Genzyme, a Sanofi Company, Industry · Terminated
Key facts
| NCT number | NCT00230607 |
|---|---|
| Title | Study of the Effects of Fabrazyme Treatment on Lactation and Infants |
| Official title | A Multicenter, Multinational Study of the Effects of Fabrazyme (Agalsidase Beta) Treatment on Lactation and Infants |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Terminated |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Fabry Disease, Alpha Galactosidase A Deficiency |
| Intervention type | Drug |
| Interventions | agalsidase beta |
| Enrollment | 7 |
| Start date | May 28, 2006 |
| Primary completion | Feb 9, 2024 |
| Completion | Feb 9, 2024 |
| First posted | Oct 3, 2005 |
| Last update posted | Apr 10, 2024 |
| Countries | Austria, United Kingdom, United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: